Previous 10 | Next 10 |
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 - ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment - Authorization enables use of baricitinib in combination with...
Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (NASDAQ: INCY) today announced a clinical collaboration to investigate the combination of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory di...
Incyte (Nasdaq:INCY) today announced that abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually from November 11-14, 2020. “We are excited to join the oncology community at th...
HQH offers investors a quarterly distribution based on 2% of the NAV. Due to the fund's significant discount, the yield shareholders actually receive is even more attractive. The fund has also been a great performer due to the pandemic. For further details see: HQH: Deep...
Image source: The Motley Fool. Incyte Corp (NASDAQ: INCY) Q3 2020 Earnings Call Nov 5, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corp (INCY) Q3 2020 Earnings Call Transcript
Incyte Corporation (INCY) Q3 2020 Earnings Conference Call November 5, 2020 08:00 AM ET Company Participants Mike Booth - Head of Investor Relations Hervé Hoppenot - Chairman, President & Chief Executive Officer Barry Flannelly - Executive Vice President, General Manager, US Steven S...
The following slide deck was published by Incyte Corporation in conjunction with their 2020 Q3 earnings call. For further details see: Incyte Corporation 2020 Q3 - Results - Earnings Call Presentation
Incyte (INCY): Q3 Non-GAAP EPS of $0.23 misses by $0.53; GAAP EPS of -$0.07 misses by $0.57.Revenue of $620.64M (+12.5% Y/Y) misses by $1.84M.Shares +0.22% PM.Press Release For further details see: Incyte EPS misses by $0.53, misses on revenue
Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended September 30, 2020; Jakafi ® (ruxolitinib) revenues of $488 million in Q3 2020 (+13% vs Q3 2019); Incyte tightens full year 2020 Jakafi revenue guidance to a range of $1.910 to $1...
- Numerous abstracts, including 7 oral presentations, highlighting data for ruxolitinib, parsaclisib, tafasitamab and ponatinib to be exhibited Incyte (Nasdaq: INCY) today announced that numerous abstracts highlighting data from its oncology portfolio will be presented at th...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...